Sign In
Buy VCEL
$45.96
-1.65 (-3.47%)
At Close: Jul 31, 2026
Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks.
04:20pm, Tuesday, 03'rd Dec 2024
None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
Here's Why Momentum in Vericel (VCEL) Should Keep going
09:51am, Monday, 11'th Nov 2024
Vericel (VCEL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our sh
Vericel Corporation (VCEL) Q3 2024 Earnings Conference Call Transcript
01:52pm, Thursday, 07'th Nov 2024
MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Eric Burns - Vice President of Finance & Investor Relations Nick Colangelo - Chief Executi
Vericel Corporation (VCEL) Reports Q3 Loss, Tops Revenue Estimates
10:11am, Thursday, 07'th Nov 2024
Vericel Corporation (VCEL) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago.
Vericel Reports Third Quarter 2024 Financial Results
07:55am, Thursday, 07'th Nov 2024
Total Revenue Growth of 27% to $57.9 Million Gross Margin of 72% and Adjusted EBITDA Growth of 84% Full-Year Profitability Guidance Raised FDA Approval and Commercial Launch of MACI Arthro in Third Qu
Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024
08:30am, Thursday, 24'th Oct 2024
CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will
Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024
09:17am, Thursday, 29'th Aug 2024
CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick
Vericel Announces FDA Approval and Commercial Availability of MACI Arthro
07:45am, Monday, 26'th Aug 2024
First Restorative Biologic Cartilage Repair Product Approved for Arthroscopic Administration Targets the Largest Segment of MACI's $3 Billion Addressable Market CAMBRIDGE, Mass., Aug. 26, 2024 (GLOBE
Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns
04:05pm, Thursday, 15'th Aug 2024
Approval Expands NexoBrid Target Customer Base to Include Approximately 20 Pediatric Burn Centers CAMBRIDGE, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in adv
Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024
08:30am, Wednesday, 07'th Aug 2024
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Co
What Makes Vericel (VCEL) a New Strong Buy Stock
01:01pm, Monday, 05'th Aug 2024
Vericel (VCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Vericel Corporation (VCEL) Q2 2024 Earnings Call Transcript
03:58pm, Thursday, 01'st Aug 2024
Vericel Corporation (NASDAQ:VCEL ) Q2 2024 Results Conference Call August 1, 2024 8:30 AM ET Company Participants Eric Burns - Vice President of Finance & Investor Relations Nick Colangelo - Chief Exe
Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates
10:06am, Thursday, 01'st Aug 2024
Vericel Corporation (VCEL) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.11 per share a year ago.
Vericel Reports Second Quarter 2024 Financial Results
07:55am, Thursday, 01'st Aug 2024
Total Revenue of $52.7 Million, with MACI Revenue Growth of 21% to $44.1 Million NexoBrid Revenue Growth of 76% Over Prior Quarter Gross Margin of 70% and Adjusted EBITDA Growth of 42% Full-Year Profi
Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer
08:30am, Monday, 22'nd Jul 2024
CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointm
